Philipp Staber, MD PhD
Physician Scientist
Associate Professor of Medicine
Program Director: Lymphoma, CLL
E-Mail: philipp.staber@meduniwien.ac.at
Tel.: +43 (0)1 40400-73782 (office)
Tel.: +43 (0)1 40400-73795 (assistant and lab)
Tel.: +43 (0)1 40400-44100 (study secretary)
Our lab undertakes basic, translation and clinical research to advance and develop novel diagnostics and treatment modalities for patients with hematological malignancies. More specifically, we study leukemias and lymphomas with particular high medical need for better therapies such as T-PLL (T-cell-prolymphocytic leukemia), and PTCL (peripheral T-cell lymphoma). Moreover, the group has been instrumental in setting up a viable biobank (Vivi-bank) at the Medical University of Vienna, which currently contains a unique set of over 1000 fully annotated viable lymphoma samples for research use.
The laboratory is composed of various research profiles, including physician scientists, which drives our multi-disciplinary approach. The basic research of the group focuses on key transcription factors of the blood system and their role in cellular differentiation, regulation of gene expression, and cancer formation. We particularly aim to understand how oncoproteins hijack physiologic programs to impact transcription factors so that they evoke hematologic cancers. Consequently, the central theme of our research is to push precision cancer medicine from a genetic centered view to a functional level where we test the feasibility and efficacy of integrating ex vivo drug screening in clinical decision making. We are especially interested in the rational design of drug combinations to break therapy resistance and generating concepts on future trial design in the age of personalized precision medicine.
In human visualization of ibrutinib-induced CLL compartment shift.
Mayerhoefer ME, Haug A, Jäger U, Pichler V, Pfaff S, Wester HJ, Hacker M, Kazianka L, Staber PB.Cancer Immunol Res. 2020 Jun 24:canimm.0880.2019. doi: 10.1158/2326-6066.CIR-19-0880. Online ahead of print. PMID: 32580942
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Review. PMID: 31292114
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB. Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27. PMID: 28972014
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB*, Superti-Furga G*. (*equal contributions) Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15. PMID: 29153976
The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells.
Staber PB, Zhang P, Ye M, Welner RS, Levantini E, Di Ruscio A, Ebralidze AK, Bach C, Zhang H, Zhang J, Vanura K, Delwel R, Yang H, Huang G, Tenen DG. Blood. 2014 Oct 9;124(15):2391-9. doi: 10.1182/blood-2014-01-550855. Epub 2014 Sep 3. PMID:25185713
Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells.
Staber PB, Zhang P, Ye M, Welner RS, Nombela-Arrieta C, Bach C, Kerenyi M, Bartholdy BA, Zhang H, Alberich-Jordà M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Orkin SH, Göttgens B, Rosenbauer F, Huang G, Tenen DG. Mol Cell. 2013 Mar 7;49(5):934-46. doi: 10.1016/j.molcel.2013.01.007. Epub 2013 Feb 8. PMID:23395001
C/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence.
Ye M, Zhang H, Amabile G, Yang H, Staber PB, Zhang P, Levantini E, Alberich-Jordà M, Zhang J, Kawasaki A, Tenen DG. Nat Cell Biol. 2013 Apr;15(4):385-94. doi: 10.1038/ncb2698. Epub 2013 Mar 17. PMID:23502316
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L. Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14. PMID:23064464
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G. Blood. 2007 Nov 1;110(9):3374-83. doi: 10.1182/blood-2007-02-071258. PMID:17690253